This article is in progress as I put together resources on the latest multiple myeloma (MM) research for patients. This article represents advanced information about multiple myeloma for patients and care-givers that already understand the basics of multiple myeloma.
If you were just diagnosed with multiple myeloma, or otherwise are new to MM, then I would recommend you explore some of the basics of multiple myeloma resources here. If you are interested in induction, or the first chemotherapy you get after a new multiple myeloma diagnosis, you should probably check here.
This article is broader look at the 2020 ASH Conference and the subsequent research.
Multiple Myeloma Treatment Definitions Cheat Sheet
K = carfilzomib = Kyprolis
R = lenalidomide = Revlimid
KRd = dexamethasone = Kd
PFS = progression-free survival (you live, and your multiple myeloma does not get any worse, i.e. progress)
ASCT = autologous stem cell transplant (the typical stem cell transplant where you collect and reimplant your own stem cells)
DRd = daratumumab + Revlimid + dexamethasone
IRD = ixaxomib + Revlimid + dexamethasone
ERd = elotuzumab + Revlimid + dexamethasone
Isa = Isatuximab
Pom= pomalidomide (usually used in place of lenalidomide aka Revlimid)
bortezomib = Velcade
ORR = overall response rate
New Multiple Myeloma Research
This paper is a doozy, covering a lot of current multiple myeloma treatments. Published in March 2020. – Novel Experimental Drugs for Treatment of Multiple Myeloma
If you want to do your own search for real multiple myeloma research use the site operator on your Google searches. The way it works is that you search for your keyword and then add ‘site:gov’ at the end. This tells Google to only return results from websites that have a .gov domain.
You can go a step further and search ‘site:nih.gov’ but you’ll miss some things that way. Generally, just making it .gov filters out a lot of the noise.
Multiple myeloma research studies and papers I am looking at:
I guess this is the big one for me if I’m going on Elotuzumab:
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma – It’s from 2018, so that’s pretty recent.
Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (2019 – says combination like elotuzumab-pomalidomide-dexamethasone will become standard 2nd line therapies. I guess I’m second line?)
Mechanisms of Action and Clinical Development of Elotuzumab (nih.gov) – This one made my head hurt, but it talks about how elotuzumab works.
Elotuzumab activates Natural Killer cells and the marks myeloma cells to be killed… but it’s complicated and involves SLAMF7, which is my new wrestling name.
According to this one, we got the order wrong… should be Elotuzumab before daratumumab. Since I was on dara for so short of time, maybe it doesn’t matter. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma